No Data
No Data
gtja: Bullish on innovative drugs policy, expected to continue to advance. Chinese patent medicine centralized procurement may face accelerated expansion.
With the support of the entire chain, innovative drugs have seen a series of bullish policies introduced in various regions, and favorable policies are expected to continue to advance in the future; centralized procurement of chinese patent medicine may accelerate its expansion.
UBS Group: Maintains a "buy" rating on Innocare (09969) with a target price raised to 8.6 Hong Kong dollars.
UBS Group believes that the research results of the second phase can support the third phase of the study.
InnoCare Pharma's Phase 2 Study of Plaque Psoriasis Drug Results Show Positive Results
InnoCare Announces Breakthrough Psoriasis Drug Results
Express News | InnoCare Pharma Ltd - Icp-488 Shows Excellent Efficacy and Safety in 12-Week Study
Express News | InnoCare Announces Phase II Study Results of Tyk2 Inhibitor Icp-488 Meet Primary Endpoint in Psoriasis Patients
No Data
No Data